Compare Ares Capital Corporation (ARCC) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ares Capital Corporation vs 22nd Century Group Inc — how do they compare? Ares Capital Corporation trades at $18.77 (market cap $13.48B), while 22nd Century Group Inc trades at $4.24 (market cap $1.46M). The key difference: Ares Capital Corporation is far larger — about 9232.9× 22nd Century Group Inc's market cap, and Ares Capital Corporation pays a 10.22% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| ARCC | XXII | |
|---|---|---|
Market Cap | $13.48B | $1.46M |
Sector | Financials | Technology |
52-Week High | $23.25 | $1.85K |
52-Week Low | $17.45 | $3.90 |
Dividend Yield | 10.22% | — |
Enterprise Value | — | -$6.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ares Capital (ARCC) trades at $18.78, up 2.01% on the day, with a bearish technical signal but strong analyst support. The stock shows a P/E of 11.52 and P/B of 0.96, trading below the consensus price target of $20.58. Recent earnings have missed expectations, with Q2 2026 results pending, while revenue declined to $1.51B in 2025 from $1.7B in 2024. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income appeal amid mixed sentiment.
ARCC presents a value opportunity with a high dividend yield and undervaluation relative to analyst targets, but faces headwinds from earnings misses and a bearish technical outlook. Risks include revenue volatility and competitive pressures in the BDC space, though institutional buy ratings suggest confidence in recovery potential. Investors should weigh income stability against growth challenges.
XXII trades at $4.23, down 2.08% on the day, amid a bearish technical signal. The company's financials show deep losses with a net income margin of -65.76% and negative ROE of -130.19% for 2026. Recent news highlights expansion of its VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. Analyst consensus is 75% buy, but earnings misses in Q4 2025 and Q1 2026 raise execution concerns.
The outlook hinges on VLN's commercial success and FDA regulatory pathway. High cash burn necessitates ongoing financing, evident in 2026's $17M financing inflow. Risks include persistent unprofitability, competitive pressures, and reliance on tobacco harm reduction narrative. Upside depends on revenue scaling and margin improvement from new retail launches.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
